Equities research analysts predict that Stemline Therapeutics Inc (NASDAQ:STML) will announce earnings per share (EPS) of ($0.49) for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for Stemline Therapeutics’ earnings, with estimates ranging from ($0.54) to ($0.38). Stemline Therapeutics posted earnings of ($0.66) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 25.8%. The firm is expected to report its next earnings report on Thursday, August 8th.
On average, analysts expect that Stemline Therapeutics will report full year earnings of ($2.14) per share for the current year, with EPS estimates ranging from ($3.01) to ($1.55). For the next year, analysts anticipate that the company will report earnings of $0.29 per share, with EPS estimates ranging from ($1.25) to $2.12. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Stemline Therapeutics.
Stemline Therapeutics (NASDAQ:STML) last announced its earnings results on Friday, May 10th. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.06). The firm had revenue of $5.05 million during the quarter, compared to the consensus estimate of $2.61 million.
In related news, COO Kenneth Hoberman sold 25,817 shares of Stemline Therapeutics stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $14.27, for a total value of $368,408.59. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 13.10% of the stock is owned by company insiders.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Metropolitan Life Insurance Co NY boosted its holdings in Stemline Therapeutics by 56.7% during the first quarter. Metropolitan Life Insurance Co NY now owns 13,358 shares of the biopharmaceutical company’s stock worth $171,000 after buying an additional 4,835 shares during the last quarter. MetLife Investment Advisors LLC boosted its holdings in Stemline Therapeutics by 54.6% during the first quarter. MetLife Investment Advisors LLC now owns 18,471 shares of the biopharmaceutical company’s stock worth $237,000 after buying an additional 6,524 shares during the last quarter. Knott David M boosted its holdings in Stemline Therapeutics by 1.3% during the first quarter. Knott David M now owns 157,795 shares of the biopharmaceutical company’s stock worth $2,028,000 after buying an additional 2,000 shares during the last quarter. Rubric Capital Management LP bought a new position in Stemline Therapeutics during the first quarter worth about $38,614,000. Finally, Fosun International Ltd boosted its holdings in Stemline Therapeutics by 362.0% during the first quarter. Fosun International Ltd now owns 267,936 shares of the biopharmaceutical company’s stock worth $3,293,000 after buying an additional 209,936 shares during the last quarter. Hedge funds and other institutional investors own 77.66% of the company’s stock.
Shares of NASDAQ:STML traded up $0.07 during midday trading on Friday, reaching $15.08. The company’s stock had a trading volume of 225 shares, compared to its average volume of 403,763. Stemline Therapeutics has a fifty-two week low of $7.82 and a fifty-two week high of $17.85. The company has a market capitalization of $658.85 million, a P/E ratio of -5.07 and a beta of 1.25. The company has a quick ratio of 5.03, a current ratio of 5.07 and a debt-to-equity ratio of 0.01. The stock’s fifty day simple moving average is $14.58.
Stemline Therapeutics Company Profile
Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.
Read More: What is the 52-week high/low?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.